open access
Application of 13-cis-retinoic acid in patients with 131I scintigraphically-negative metastases of differentiated thyroid carcinoma
open access
Abstract
Material and methods: Between 1999 and 2005, 13-cis-retinoic acid was used in 11 patients with disseminated PTC and high serum level of thyroglobulin (Tg) before 131I treatment (2 patients were treated twice - 13 treatment cycles in total). Side effects in skin and mucous membranes were observed in all the patients, however, their intensity did not require termination of the therapy.
Results: Increase of iodine uptake was observed in 5 patients (45%). Decreased Tg concentration was observed in 9 patients. In that group, increased 131I uptake was observed in 4 patients with distant metastases. All determinations of Tg concentrations were carried out under TSH stimulation.
Conclusions: 13-cis-retinoic acid causes an increase of radioiodine uptake in around half of treated patients, however, the follow-up of these patients indicates that this increase does not result in either full remission or even stabilisation of neoplastic disease. The possibility should be considered to use cis-retinoic acid as an independent therapeutic approach in patients with radioiodine non-avid foci of thyroid carcinoma especially those showing high expression of RARb and RXRg receptors.
Abstract
Material and methods: Between 1999 and 2005, 13-cis-retinoic acid was used in 11 patients with disseminated PTC and high serum level of thyroglobulin (Tg) before 131I treatment (2 patients were treated twice - 13 treatment cycles in total). Side effects in skin and mucous membranes were observed in all the patients, however, their intensity did not require termination of the therapy.
Results: Increase of iodine uptake was observed in 5 patients (45%). Decreased Tg concentration was observed in 9 patients. In that group, increased 131I uptake was observed in 4 patients with distant metastases. All determinations of Tg concentrations were carried out under TSH stimulation.
Conclusions: 13-cis-retinoic acid causes an increase of radioiodine uptake in around half of treated patients, however, the follow-up of these patients indicates that this increase does not result in either full remission or even stabilisation of neoplastic disease. The possibility should be considered to use cis-retinoic acid as an independent therapeutic approach in patients with radioiodine non-avid foci of thyroid carcinoma especially those showing high expression of RARb and RXRg receptors.
Keywords
13-cis-retinoic acid; differentiated thyroid carcinoma; radioiodine; treatment
About this articleTitle
Application of 13-cis-retinoic acid in patients with 131I scintigraphically-negative metastases of differentiated thyroid carcinoma
Journal
Issue
Article type
Original paper
Pages
403-406
Published online
2006-07-07
Page views
495
Article views/downloads
1177
Bibliographic record
Endokrynol Pol 2006;57(4):403-406.
Keywords
13-cis-retinoic acid
differentiated thyroid carcinoma
radioiodine
treatment
Authors
Zbigniew Adamczewski
Jacek Makarewicz
Sławomir Mikosiński
Małgorzata Knapska-Kucharska
Anna Gunerska-Szadkowska
Lidia Oszukowska
Anzelmina Karwowska
Andrzej Lewiński
